---
schema_version: "secwatch.filing_event.v1"
accession: "0001819790-22-000029"
form_type: "8-K"
ticker: "TARS"
cik: "0001819790"
company_name: "Tarsus Pharmaceuticals, Inc."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T01:03:26.140081+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tarsus Q2 net loss $5.7M; TP-03 NDA submission for Demodex blepharitis on track

## Summary
- Net loss of $5.7M vs net income of $6.3M in Q2 2021; revenue $15.3M from LianBio partnership.
- Cash and equivalents $245.4M as of June 30, 2022; runway into at least 2026.
- TP-03 met all endpoints in Saturn-2 Phase 3; NDA submission expected in H2 2022.
- Initiated Ersa Phase 2a trial of TP-03 for Meibomian Gland Disease.
- Expecting Phase 1b data for TP-05 Lyme disease prevention in H2 2022.

## SEC filing metadata
- accession: 0001819790-22-000029
- form_type: 8-K
- ticker: TARS
- cik: 0001819790
- company_name: Tarsus Pharmaceuticals, Inc.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819790/000181979022000029/0001819790-22-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819790/000181979022000029/tars-20220811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001819790-22-000029
- JSON: https://secwatch.observer/filing/0001819790-22-000029.json
- Plain text: https://secwatch.observer/filing/0001819790-22-000029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.